What are the key points for staging Gastric (stomach) Cancer from Stage 0 (Carcinoma in situ) to Stage IV?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Staging of Gastric Cancer

The key points for staging gastric cancer from Stage 0 to Stage IV are based on the AJCC/UICC staging system, which considers the tumor size and extent (T), lymph node involvement (N), and presence of metastasis (M) 1.

  • Stage 0 (Carcinoma in situ): The cancer is confined to the mucosa and has not invaded the basement membrane.
  • Stage I: The cancer has invaded the submucosa (T1) and may have involvement of 1-2 regional lymph nodes (N1).
  • Stage II: The cancer has invaded the muscularis propria (T2) or the subserosa (T3) and may have involvement of 3-6 regional lymph nodes (N2).
  • Stage III: The cancer has invaded the serosa (T4a) or has spread to nearby organs (T4b) and may have involvement of 7 or more regional lymph nodes (N3).
  • Stage IV: The cancer has spread to distant organs, such as the liver, lungs, or peritoneum (M1).

Key Considerations

When staging gastric cancer, it is essential to evaluate at least 16 lymph nodes to ensure accurate staging 1. The Lauren classification can also be used to classify gastric adenocarcinoma into intestinal, diffuse, or mixed types based on histological growth patterns 1.

Diagnostic Modalities

Various diagnostic modalities, such as endoscopic ultrasound (EUS), CT scanning, and FDG-PET, can be used to assess the depth of tumor invasion and nodal involvement 1. However, the accuracy of these modalities can vary, and a combination of modalities may be necessary for accurate staging.

Pathological Evaluation

The pathological evaluation of gastric cancer specimens should include meticulous resection, collection, and preparation of specimens, as well as evaluation of lymph node metastasis and carcinomatous nodules 1. The Borrmann classification can also be used to classify gastric cancer into four subtypes based on tumor morphology.

Treatment Implications

Accurate staging of gastric cancer is crucial for determining the optimal treatment strategy, which may include surgery, chemotherapy, radiation therapy, or a combination of these modalities 1.

From the Research

Staging of Gastric Cancer

The staging of gastric cancer is critical for determining the prognosis and survival prediction of patients. The American Joint Committee on Cancer (AJCC) staging system is the most widely applied system to determine the disease's prognosis and survival prediction 2. The staging system incorporates the depth of tumor invasion, extent of lymph node, and distant metastases.

Key Points for Staging Gastric Cancer

  • Stage 0: Carcinoma in situ, where the cancer is limited to the mucosa and has not invaded the basement membrane 3
  • Stage I: The cancer has invaded the submucosa, but has not extended beyond the gastric wall 3
  • Stage II: The cancer has invaded the muscularis propria or the subserosa, but has not extended beyond the gastric wall 3
  • Stage III: The cancer has extended beyond the gastric wall, but has not metastasized to distant sites 3
  • Stage IV: The cancer has metastasized to distant sites, such as the liver, lungs, or peritoneum 3

Imaging Modalities for Staging Gastric Cancer

  • Multidetector computed tomography (MDCT) is the preferred technique for staging gastric cancer, as it can assess tumor depth, nodal disease, and metastases 4
  • Endoscopic ultrasonography is more accurate for assessing the depth of wall invasion in early cancer, but is limited in the assessment of advanced local or stenotic cancer and detection of distant metastases 4
  • Positron emission tomography (PET) is most useful for detecting and characterizing distant metastases 4

Clinical and Pathological Staging

  • Accurate categorization of invasive depth and lymph node metastasis is fundamentally critical for prognostic assessment and decision making regarding subsequent therapies after surgery for gastric cancer 3
  • The quality of standardized pathological diagnosis of gastric cancer requires improvement, and a new development in TNM staging and a way to improve clinical and pathological quality control of gastric cancer is needed 3

Surgical Approaches

  • Resection is the cornerstone of cure for gastric adenocarcinoma, and a D2 lymphadenectomy is preferred for curative-intent resection of gastric cancer 5
  • At least 16 lymph nodes should be assessed for adequate staging of curative-resected gastric cancer 5
  • Gastric cancer surgery should aim to achieve an R0 resection margin, and patients should be referred to higher-volume centers and those that have adequate support to manage potential complications 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Clinical and pathological staging of gastric cancer: Current perspectives and implications.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2020

Research

Gastric carcinoma: imaging diagnosis, staging and assessment of treatment response.

Cancer imaging : the official publication of the International Cancer Imaging Society, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.